Multi-Site Validation Study Confirms Diagnostic-Grade AI Biomarker Detection from Routine Brightfield Images
核心洞察
Panakeia (搜索) published a multi-site clinical validation study in Clinical Breast Cancer (搜索) demonstrating that its PANProfiler Breast (搜索) (ER (搜索), PR (搜索), HER2 (搜索)) software accurately identifies key molecular biomarkers directly from routine brightfield images.
The UKCA-marked AI medical device delivered diagnostic-grade performance with high test-replacement rates and strong concordance to gold-standard pathology results across multiple independent healthcare institutions.
The findings confirm the platform's scalability across cancer types, building on prior colorectal cancer (搜索) validation and supporting faster, tissue-preserving molecular profiling in minutes rather than weeks.
Panakeia (搜索), a world-leading in silico multi-omics company, announced the publication of a multi-site clinical validation study in Clinical Breast Cancer (搜索) demonstrating that its PANProfiler Breast (搜索) (ER (搜索), PR (搜索), HER2 (搜索)) software—a UKCA-marked medical device—accurately identifies critical molecular biomarkers (ER, PR, and HER2) directly from routine brightfield images of tissues and cells across multiple sites. The announcement, dated September 8, 2026 from Cambridge, UK, positions the technology as a scalable foundation for oncology across multiple cancer types and biomarkers.
The research marks an important milestone by proving that Panakeia (搜索)'s technology works reliably in clinical practice regardless of variations in tissue preparation or image quality across different laboratories. Critically, it confirms that the platform's core ability to detect biomarkers directly from routine brightfield images translates across multiple cancer types, laying a strong foundation for widespread clinical use.
Building on Colorectal Cancer Validation
These findings build upon the platform's established success in colorectal cancer (搜索) (PANProfiler Colorectal), published in npj Digital Medicine. That earlier study proved the platform matches gold-standard accuracy for both MSI (搜索) (DNA) and MMR (搜索) (protein) biomarkers, operates robustly across multiple clinical sites, and delivers results in a significantly faster timeframe.
By also demonstrating similar high-performance molecular profiling in breast cancer (搜索), Panakeia (搜索) has confirmed the platform's capability to deliver consistent, diagnostic-grade insights across diverse cancer types and biomarker classes. The technology is proving to be a scalable foundation for oncology, capable of uncovering complete biological blueprints across any major indication. Unlocking these total biological blueprints directly from routine imaging provides biopharma researchers with the insights needed to accelerate target discovery, while empowering clinicians to match patients to effective targeted therapies faster.
Diagnostic-Grade Performance and Standalone Clinical Utility
The study highlights several key attributes of the technology. PANProfiler Breast (搜索) (ER (搜索), PR (搜索), HER2 (搜索)) delivers a high test-replacement rate with strong concordance to gold-standard pathology results, moving the technology beyond a screening aid to a repeatable, reproducible tool for standalone molecular profiling.
The software provides a digital alternative to traditional "wet-lab" assays, delivering equivalent insights in minutes rather than weeks without requiring additional tissue destruction. For patients and clinical care teams, this drastically reduces anxious waiting periods, preserves limited tissue samples, and provides immediate clarity on next steps and targeted therapy pathways.
Validation across multiple independent healthcare institutions proved consistent performance even when routine brightfield images were processed on different types of digital scanners. Additionally, the AI identified opportunities for more refined patient stratification by uncovering biological nuances that traditional testing may miss—findings previously presented at SABCS, AACR, and ESMO Breast—ensuring more patients can be matched to the right targeted therapies.
Leadership Perspective
Pahini Pandya, Founder and Chief Executive Officer of Panakeia (搜索), commented: "The publication of this study is another important milestone in our journey to make the highest standard of precision medicine accessible to doctors and patients across the world. By proving that we can deliver diagnostic-grade biological insights from routine brightfield images, we are providing the essential tools needed to transform clinical decision-making and ensure patients receive personalized, life-saving therapies without delay."
Pandya added: "Our preliminary results recently presented at AACR 2026 show where this is headed—moving beyond these static biomarkers to uncover the functional hallmarks of cancer. By providing this total biological blueprint, we are not only improving care today but providing biopharma partners with the insights needed to accelerate drug development and reduce failure rates in the clinic."
Setting the Gold Standard for Healthcare AI
Having demonstrated the robust performance and scalability of both clinical products and the underlying platform, Panakeia (搜索) is leading the industry in establishing rigorous evidence standards for safe, patient-centric AI. The company is actively working with international regulatory bodies and industry partners, including participation in the Friends of Cancer Research Digital PATH Project alongside the FDA, and the UK MHRA's AI Airlock programme, to define regulatory roadmaps and safely bring AI-driven diagnostic solutions to patients worldwide.
About the Technology
PANProfiler Breast (搜索) (ER (搜索), PR (搜索), HER2 (搜索)) is a UKCA-marked AI software powered by Panakeia (搜索)'s proprietary technology that determines ER, PR, and HER2 biomarker status directly from routine brightfield images of cells and tissues. Built using a biology-first approach with AI trained on petabytes of population-scale data, the software provides diagnostic-grade results in minutes, enabling faster treatment decisions and improved patient stratification without the need for additional wet-lab assays.
The broader PANProfiler platform determines multi-omic biomarker status across DNA, RNA, proteins, and metabolites directly from routine brightfield images of tissues and cells. The platform can profile thousands of biomarkers in more than 30 cancer types, supporting drug discovery, clinical development, and patient care. Panakeia (搜索)'s technology has been independently validated in peer-reviewed publications, including Nature Communications Medicine and Clinical Breast Cancer (搜索), and two UKCA-marked clinical products derived from the platform are deployed in hospitals, enabling faster and more accessible precision diagnostics.